[posting]57558867[/posting]April 9, 2018
We are an "emerging growth company" as defined under Section 2(a) of the Securities Act of 1933, and, as such, we have elected to comply with certain reduced public company reporting requirements for this prospectus and may elect to comply with reduced public company reporting requirements for future filings.[/u]
...und das im schizophrenen Land der Bausparverträge und des Hochrisiko-Kapitalmarktes
aus: https://www.sec.gov/Archives/edgar/data/1340243/000119312518…
https://seekingalpha.com/article/4162869-morphosys-finalizes…
=>
- MorphoSys intends to raise $230.2 million in gross proceeds from an IPO of its ADSs.
- Assuming a successful IPO, the company's post-IPO market capitalization would be approximately $3.0 billion, excluding the effects of underwriter over-allotment options.
- expected IPO Pricing Date: Wednesday, April 18, 2018
...
As of December 31, 2017, the company had $92 million in cash and $68.2 million in total liabilities.
=> der Druck im Zylinder wächst...